PEG-Coated Liposomes Supercharge Plant Compound's Fight Against Kidney Disease
Scientists engineered nanoparticle shells around isoquercitrin, boosting its bioavailability 4.5-fold and showing promise against chronic kidney disease.
Summary
Isoquercitrin, a plant-derived flavonoid with anti-inflammatory and antioxidant properties, has long been hindered by poor water solubility and rapid clearance from the body. Researchers at Jiangsu University addressed this by encapsulating isoquercitrin in PEG-modified liposomes using a thin film dispersion method. The optimized nanoparticles measured 185 nm with nearly 98% encapsulation efficiency. In rat pharmacokinetic studies, the liposomal formulation achieved a 4.54-fold improvement in systemic exposure, 1.63-fold longer half-life, and 2.07-fold higher peak concentration versus free isoquercitrin. Mouse models of chronic kidney disease showed promising improvements in renal function markers. This nanodelivery approach could meaningfully extend the therapeutic reach of natural compounds previously limited by poor pharmacokinetics.
Detailed Summary
Chronic kidney disease (CKD) affects hundreds of millions globally and remains difficult to treat with existing therapies. Natural plant compounds like isoquercitrin (IQ) — a glycoside form of quercetin — show strong antioxidant, anti-inflammatory, and renoprotective effects in laboratory settings, yet their clinical translation has been stalled by low solubility and rapid elimination from circulation.
To overcome these barriers, researchers prepared polyethylene glycol (PEG)-modified liposomes encapsulating isoquercitrin (IQ-L) using the thin film dispersion method. Formulation variables were systematically optimized through One Factor at a Time (OFAT) testing combined with response surface methodology, yielding nanoparticles with a mean size of 185.48 nm, polydispersity index of 0.252, zeta potential of -33.88 mV, and encapsulation efficiency of 97.84% — all favorable characteristics for a stable, long-circulating drug delivery system.
In vitro release studies confirmed that IQ-L released the active compound more gradually and completely than free IQ. Pharmacokinetic studies in rats demonstrated dramatic improvements: area under the concentration-time curve increased 4.54-fold, elimination half-life extended 1.63-fold, and peak plasma concentration rose 2.07-fold. These gains reflect the well-known stealth properties of PEGylation, which reduces immune recognition and slows clearance.
In a mouse model of CKD, animals receiving IQ-L showed promising improvements in renal function markers compared to controls, suggesting genuine therapeutic potential beyond improved pharmacokinetics alone.
Caveats remain significant: the study relied on animal models, and efficacy and safety in humans are untested. Long-term toxicity of the liposomal formulation, manufacturing scalability, and clinical endpoints in CKD patients require future investigation before this approach can advance toward clinical use.
Key Findings
- PEG-modified isoquercitrin liposomes achieved 97.84% encapsulation efficiency with stable 185 nm particle size.
- Systemic drug exposure (AUC) increased 4.54-fold compared to unmodified isoquercitrin in rat studies.
- Plasma half-life extended 1.63-fold and peak concentration rose 2.07-fold with liposomal formulation.
- Mouse CKD models showed improved renal function markers after IQ-L treatment.
- PEGylation significantly enhanced in vivo retention and solubility of a previously bioavailability-limited natural compound.
Methodology
Liposomes were prepared via thin film dispersion and optimized using OFAT and response surface methodology. Pharmacokinetic parameters were assessed in rats; renal therapeutic effects were evaluated in a mouse CKD model. Only the abstract was available for review, limiting access to full experimental details.
Study Limitations
All efficacy data derive from rodent models, and human translation remains unproven. Long-term safety, manufacturing scalability, and effects on established CKD clinical endpoints have not been assessed. Full methodology was unavailable as only the abstract was accessible.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.